OH2 Injection in Combination With HX008 for Melanoma.

  • STATUS
    Recruiting
  • End date
    Nov 30, 2022
  • participants needed
    60
  • sponsor
    Wuhan Binhui Biotechnology Co., Ltd.
Updated on 5 January 2022
measurable disease
metastasis
liver metastasis
mitomycin
targeted therapy

Summary

This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma.

OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

Description

The trial is a phase Ib study evaluating the safety and efficacy of OH2 injection combined with HX008 injection in patients with Melanoma.

In the Phase Ib dose escalation trial, two doses (1x10e6, 1x10e7 CCID50/mL) of OH2 will be combined with HX008(at a fixed dose of 200mg) will be tested.

In the Phase Ib dose expansion trial, OH2(1x10e7 CCID50/mL) will be injected individually in the first week, followed by every two weeks while HX008(200 mg) will be injected every three weeks after the first injection which will be in the second week.

Blood samples will be collected and radiological imaging will be performed to evaluate safety and efficacy during the trial. Besides, patients will be subjected to cutaneous swabs, and blood/urine/feces sampling to determine virus shedding. Participating patients will be evaluated for objective response rate, progression free survival and overall survival.

Details
Condition Melanoma
Treatment OH2 injection, HX008 injection
Clinical Study IdentifierNCT04616443
SponsorWuhan Binhui Biotechnology Co., Ltd.
Last Modified on5 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

The non-operative stage III or stage IV malignant tumor patients with clear diagnosis by pathology
Patients who have failed in conventional treatment (including PD-1 monotherapy) (disease progression or intolerance) or who have failed in previously assisted PD-1 monotherapy (last assisted PD-1 treatment relapse or metastasis within 6 months)
Patients with Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1, expected survival time more than 3 months
Prior anti-tumor treatment (including endocrine, chemical/ radiotherapy,targeted therapy) was over 4 weeks (more than 6 weeks of discontinuation using nitroso-and mitomycin-based chemotherapy) and was recovered to grade 1 from the side effects of prior treatment
There is at least one measurable lesion that is suitable for intratumoral injection. The measured tumor focus is defined as the longest diameter ≥ 5 mm
Asymptomatic central nervous system metastasis, or treated asymptomatic brain metastasis patients, must be examined by a computerized fault scan (CT) or MRI for disease-free progression, stable for at least 3 months, and at least 4 weeks without steroid medication
(a) WBC≥3.0×109/L,ANC≥2.0×109/L ,PLT≥100×109/L,Hb≥90 g/L; (b) BUN and Scr. were in the upper limit of 1.5 times of the normal value; (c) TBIL≤ 1.5 times the upper limit of the normal value. (d) ALT and AST ≤ 2.5 times the upper limit of normal value; The value of patients with liver metastasis did not exceed 5 times the upper limit of normal value. (e) Coagulation function is normal (PT and APPT are within 1.5 times of the upper limit of normal value)
Female subjects and their spouses received effective contraceptives during and within 3 months of treatment
Subjects with herpes in the reproductive organs needed three months after the end of herpes
The informed consent was voluntarily signed and the expected compliance was good

Exclusion Criteria

Severe medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, severe infection, active digestive tract ulcer, abnormal immune function (including, but not limited to, rheumatoid arthritis, lupus erythematosus, Sjogren's syndrome, etc.)
Significant surgery is expected to be performed during the 28-day screening period during the study period
Patients had active infections or unexplained fevers (over 38.5℃)during screening and before the first drug use
Past or present immunodeficiency diseases
The lesions do not meet the requirements of injection capacity(1ml) in the tumor body
Pregnant or lactating women
Other experimental therapies or antiviral therapy are used or are being used within 4 weeks of treatment
Allergy to herpes virus and drug ingredients
History of primary grape-film melanoma or other malignant tumors in the 5 years prior to treatment
History of tuberculosis, or have tuberculosis at the time of screening
Suffering from sudden lung disease, intersex lung disease, intersex pneumonia, pulmonary fibrosis, acute lung disease, radioactive pneumonia etc
Patients with active autoimmune diseases or with a history of autoimmune diseases that may relapse, except for
Type I diabetes with stable condition after taking a fixed dose of insulin
Hypothyroidism
Controlled celiac disease
Skin diseases that do not require systemic treatment
Any other disease that does not re-occur without external triggers
Concurrent medical condition requiring the use of cortisol (>10mg/day prednisone or
The researchers believe that there is any reason why the patient is not suitable to participate in this trial
equivalent dose) or other systematic immunosuppressive medications within 14
days before the study treatment, except for inhalation or topical
corticosteroids no more than 10 mg/day prednisone or equivalent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note